Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia
1997

IgA Responses to HPV-16 E2 Protein in Cervical Neoplasia

Sample size: 45 publication Evidence: moderate

Author Information

Author(s): L Rocha-Zavaleta, D Jordan, S Pepper, G Corbitt, F Clarke, NJ Maitland, CM Sanders, JR Arrand, PL Stern, SN Stacey

Primary Institution: Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK

Hypothesis

The study investigates the association between serological IgA responses to the HPV E2 protein and the stages of cervical neoplasia.

Conclusion

The IgA antibody response to the E2 protein varies with the stage of cervical neoplasia, being higher in lower grades and lower in cervical carcinoma patients.

Supporting Evidence

  • Serum IgA levels against the E2 protein were elevated in CIN patients relative to normal controls.
  • Lower levels of IgA were observed in cervical carcinoma patients compared to CIN patients.
  • The highest antibody levels were seen in lower grades of neoplasia up to CIN 2.

Takeaway

This study found that people with early stages of cervical neoplasia have higher levels of a specific antibody, but those with cervical cancer have lower levels.

Methodology

The study used enzyme-linked immunosorbent assays (ELISA) to detect IgG and IgA responses in serum samples from cervical neoplasia patients and controls.

Limitations

The study is cross-sectional and does not provide information on the kinetics of the IgA response over time.

Participant Demographics

The study included 45 cervical carcinoma patients, 27 non-genital cancer patients, and 72 colposcopy patients, with a range of ages from 21 to 74 years.

Statistical Information

P-Value

p<0.0002

Confidence Interval

95% confidence interval 4.2-254.3

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication